Recently, MabPlex International Biomedical Co., Ltd. (MabPlex International, hereinafter referred to as Maibri), a company specializing in CDMO services for biomacromolecules, announced that it has recently completed its first financing since its establishment. This round of financing was led by investment institutions such as SDIC and Shenzhen Venture Capital, with a financing amount of 400 million yuan. This is also the largest single financing in the domestic macromolecular CDMO field.
Dr. Fang Jianmin, Chairman of Mai Bairui, said: The financing will be used to upgrade the technology platform of Mai Bairui, the phase III clinical samples of Hangzhou Pharmaceuticals and the expansion of commercial production capacity, as well as the company's international strategic layout.
In the past 2018, Maibri successfully obtained the biopharmaceutical drug production license, and the Maibrui Phase II GMP production workshop was officially opened, and 2000 liters of cell culture has been carried out. The production workshop can reach a maximum of 36,000 liters of cell culture scale, and can simultaneously carry out GMP production of multiple biopharmaceutical products to meet the needs of phase III clinical samples and commercial production.
In terms of international strategy, the US-based San Diego R&D Center was officially launched in the third quarter of 2018, focusing on the development of the drug and ADC drug processes. Several development projects have been launched.
The Maibri Shanghai R&D Center is scheduled to be officially launched in the first quarter of 2019 and will focus on process development of antibody drugs. At the same time, the US and Australian INDs that Maibray reported for customers were approved at one time, and the pace of globalization was further accelerated.
Maibray is a company specializing in CDMO services for biopharmaceuticals. It has three R&D and production centers in Yantai, Shanghai and San Diego. It can provide macromolecules, antibody-conjugated drugs, recombinant protein drugs and other macromolecular biopharmaceuticals to customers around the world. One-stop outsourcing services such as R&D, production, IND filing, clinical sample preparation, and even commercial GMP production.
Maibrui currently has 50,000 square meters of production facilities, a total of 9 single antigen liquid GMP production lines, 2 ADC raw liquid production lines, 1 monoclonal antibody production line, 1 ADC preparation production line, can provide 200 to 12000 liters (6 * 2000) The scale of biopharmaceutical GMP production can help customers accelerate the progress of clinical trials and drug marketing.
Maibrui has a management team with rich international experience and a well-organized professional team. It has established a strict quality system and GMP production specifications. It can complete the IND of innovative bio-pharmaceuticals and biosimilar drugs in accordance with FDA, EMA and NMPA requirements. / BLA declaration.
At present, Maibri has provided CDMO services to dozens of pharmaceutical companies around the world. It has completed more than 10 IND declarations, including IND declarations in the US and Australia, and has provided Phase I and Phase II clinical trials for many customers. Production service using samples.
In the first half of 2019, Maibri will also complete multiple IND declarations, most of which are Chinese and American double newspapers.
Improve Immunity Plant Extract
Improve Immunity Plant Extract,Ginseng Extract,Mulberry Powder,Seabuckthorn Powder
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.ffsinuoteplant.com